{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"}],"units":"Participants"}],"description":"Number of patients with relapsed/progressive disease post-transplant. The effectiveness of pre- and post-transplant rituximab in decreasing the rate of relapse will be evaluated.","groups":[{"description":"Patients receive rituximab IV, pre- and post-transplant, on days -3, 10, 24, and 38. Patients undergo donor peripheral blood stem cell transplant on day 0. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\nrituximab: Given IV\n\nperipheral blood stem cell transplantation: Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation\n\nnonmyeloablative allogeneic hematopoietic stem cell transplantation: Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation\n\npharmacological study: Correlative studies\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Rituximab Pre- and Post-transplant)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"At 18 months","title":"Disease Relapse Rate","type":"PRIMARY","unitOfMeasure":"Participants"}